23:43 , Nov 12, 2018 |  BC Extra  |  Financial News

CStone lines up for Hong Kong IPO

With an anti-PD-L1 mAb in Phase III testing and cornerstone investors such as WuXi Ventures and Boyu Capital, immuno-oncology company CStone Pharmaceuticals Co. Ltd. (Suzhou, China) on Monday proposed to list on the Hong Kong...
19:53 , Nov 9, 2018 |  BioCentury  |  Politics, Policy & Law

Buckle-up, turbulence ahead in Washington

The midterm elections’ outcome will create deafening political noise about drug prices and great discomfort for pharmaceutical company executives. The effects on the biopharma industry will be tangible, but far more modest than the fiery...
20:02 , Nov 2, 2018 |  BC Week In Review  |  Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Oct. 29,...
19:59 , Nov 2, 2018 |  BC Week In Review  |  Company News

Pfizer likely to remove lid on drug price increases in January

Chairman and CEO Ian Read said Pfizer Inc. (NYSE:PFE) will likely end its agreement to defer drug price increases and return to "business as normal" by year end. Read's comments, which came during the pharma’s...
22:55 , Oct 30, 2018 |  BC Extra  |  Company News

Management tracks: Blueprint, Clovis

Ahead of the anticipated 2019 launch of avapritinib, Blueprint Medicines Corp. (NASDAQ:BPMC) hired Christina Rossi into the newly created role of chief commercial officer. She was the multiple sclerosis business unit head of North America...
22:30 , Oct 30, 2018 |  BC Extra  |  Company News

Pfizer likely to remove lid on drug price increases in January

Chairman and CEO Ian Read said Pfizer Inc. (NYSE:PFE) will likely end its agreement to defer drug price increases and return to "business as normal" by year end. Read's comments, which came during the pharma’s...
14:43 , Oct 30, 2018 |  BC Extra  |  Financial News

With clear FDA path, Clementia raises $70.2M

Days after revealing regulatory plans for its therapy for a rare bone disease, Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) raised $70.2 million in a bumped-up follow-on offering. Clementia priced 5.3 million shares at $13.25 late Monday, hours...
21:43 , Oct 26, 2018 |  BioCentury  |  Finance

Springing into Cerevel

Bain Capital is following the blueprint for Pfizer Inc. (NYSE:PFE) spinout SpringWorks Therapeutics LLC and applying it on a larger scale to Cerevel Therapeutics LLC, which will develop Pfizer’s discontinued neuroscience pipeline with $350 million...
19:52 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Clementia jumps on NDA plans for unmet rare bone disease

Clementia Pharmaceuticals Inc. (NASDAQ:CMTA) climbed $4.16 (40%) to $14.50 on Oct. 24 after announcing regulatory plans for palovarotene that could put the therapy first in line to gain FDA approval for fibrodysplasia ossificans progressiva (FOP)....
22:55 , Oct 25, 2018 |  BC Innovations  |  Targets & Mechanisms

Blueprint for selectivity

Blueprint Medicines Corp. is making the jump from cancer to rare disease with an inhibitor for the rare pediatric bone disease FOP that sets the company up against at least two competitors further ahead in...